Carcinoma, Non-small Cell Lung Cancer Clinical Trial
— CheckMate 79XOfficial title:
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy
| Verified date | December 2023 |
| Source | Bristol-Myers Squibb |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | May 13, 2026 |
| Est. primary completion date | December 17, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria - Histologically or cytologically-documented Stage IV A/B non-small cell lung Cancer, stage IIIB/C disease failed concurrent chemoRT. - ECOG Performance Status of = 1. - Radiologically-documented disease progression on one anti-PD-1/anti-PD-L1 therapy and one platinum-based doublet regimen given either concurrently or sequentially within 90 days after the last dose of anti-PD-(L)1. - All participants must have tumor tissue submitted prior to randomization, either a recent archival sample obtained on/after the date of disease progression of the last prior anticancer therapy and within 3 months prior to enrollment, or a fresh biopsy obtained during the screening period. - Prior toxicities must have resolved to grade =1. - Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test and must not be breastfeeding. - Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception. In addition, male participants must be willing to refrain from sperm donation during this time and must agree to follow instructions for method(s) of contraception. Azoospermic males are exempt from contraceptive requirements as well as WOCBP who are continuously not heterosexually active, however, a pregnancy test will still be required. Exclusion Criteria - Prior treatment with Docetaxel. - Untreated CNS metastases, carcinomatous meningitis or leptomeningeal metastases. - Any tumor invading the Superior Vena Cava other blood vessel, GI Tract or Trachea. - EGFR mutations, ALK translocations, ROS1 translocations which are sensitive to inhibitor therapy. - History of cerebrovascular accident and coagulation disorders. - Participants with interstitial lung disease, history of cerebrovascular accident or history of abdominal fistula, gastrointestinal perforation, bowel obstruction, intra-abdominal abscess or grade 3-4 bleeding event within 6 months prior to randomization. - Known toxicity on prior checkpoint inhibitor treatment. - Participants who received more than one line of anti- PD-1/PD-L1 treatment. - Participants who received previous CTLA-4 inhibitor treatment. - Participants with known BRAF V600E mutation which are sensitive to available targeted inhibitor therapy are excluded. - Other protocol-defined Inclusion/Exclusion criteria apply. |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Local Institution | Buenos Aires | Distrito Federal |
| Argentina | Local Institution | Buenos Aires | Distrito Federal |
| Argentina | Local Institution | Caba | Distrito Federal |
| Argentina | Local Institution | Capital | Distrito Federal |
| Argentina | Local Institution | Ciudad Autónoma De Buenos Aires | Buenos Aires |
| Belgium | Local Institution | Charleroi | |
| Belgium | Local Institution | Gilly | |
| Belgium | Local Institution | Leuven | |
| Denmark | Local Institution | Copenhagen Ø | |
| Greece | Local Institution | Athens | |
| Greece | Local Institution | Neo Faliro | |
| Mexico | Local Institution | Ciudad de México | Distrito Federal |
| Mexico | Local Institution | Heroica Puebla de Zaragoza | Puebla |
| Mexico | Local Institution | Torreon | Coahuila |
| Mexico | Local Institution | Zapopan | Jalisco |
| Netherlands | Local Institution | Amsterdam | |
| Netherlands | Local Institution | Rotterdam | |
| Norway | Local Institution | Oslo | |
| Poland | Local Institution | Krakow | |
| Poland | Local Institution | Warszawa | Mazowieckie |
| Romania | Local Institution | Craiova | |
| Romania | Local Institution | Timisoara | |
| United States | Local Institution | Detroit | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| Bristol-Myers Squibb | Clovis Oncology, Inc., Eli Lilly and Company, Exelixis |
United States, Argentina, Belgium, Denmark, Greece, Mexico, Netherlands, Norway, Poland, Romania,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall Reponse Rate (ORR) using RECIST 1.1 per Blinded Independent Central Review (BICR) assessment | approximately 33 months | ||
| Secondary | Overall Survival (OS) | Up to 5 Years | ||
| Secondary | Duration of Response (DOR) by BICR using RECIST 1.1 | approximately 33 months | ||
| Secondary | Progression-Free Survival (PFS) by BICR using RECIST 1.1 | Up to 5 Years | ||
| Secondary | Incidence of Adverse Events (AEs) | Up to 5 Years | ||
| Secondary | Incidence of Serious Adverse Events (SAEs) | Up to 5 Years | ||
| Secondary | Incidence of Select AEs | Up to 5 Years |